Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study

BACKGROUND: Low efficacy of miltefosine in the treatment of visceral leishmaniasis was recently observed in Eastern Africa. OBJECTIVES: To describe the pharmacokinetics and establish a pharmacokinetic/pharmacodynamic relationship for miltefosine in Eastern African patients with visceral leishmaniasi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Antimicrob Chemother
Autores principales: Dorlo, Thomas P C, Kip, Anke E, Younis, Brima M, Ellis, Sally J, Alves, Fabiana, Beijnen, Jos. H, Njenga, Simon, Kirigi, George, Hailu, Asrat, Olobo, Joseph, Musa, Ahmed M, Balasegaram, Manica, Wasunna, Monique, Karlsson, Mats O, Khalil, Eltahir A G
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2017
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5890687/
https://ncbi.nlm.nih.gov/pubmed/28961737
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dkx283
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares